Quality of hospital, nursing home impacts readmissions

Laura Pedulli | | Health Exec | Quality

Patients discharged from higher-quality hospitals or who received care in higher-quality nursing homes are less likely to be readmitted to a hospital within 30 days, according to a study published in AMJC Managed Markets Network.

 

Researchers conducted a cohort study of 1,382,477 individual hospitalizations discharged to 15,356 nursing homes from 3,683 hospitals between 2006 and 2008. Data studied included Medicare claims and enrollment records, Minimum Data Set, Online Survey Certification and Reporting Dataset, Hospital Compare and the American Hospital Association Database. 

 

Read more below:

Influence of Hospital and Nursing Home Quality on Hospital Readmissions

Laura Pedulli

Related Content

FDA commissioner, a veteran cardiologist, highlights ongoing issues with US healthcare system
FDA commissioner urges health systems to strengthen AI quality oversight
The top 25 children's heart hospitals in the US
Study ranks US health system dead last among wealthy nations
The 25 top US hospitals for diabetes care
The 25 best heart hospitals in the United States

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.